



BACKGROUND

Executive Biographies: Actavis Senior Leadership Team

Actavis plc's (NYSE: ACT) senior management team represents exceptional industry expertise drawn from the talent pool of both Actavis and Forest Laboratories. The leadership organization is structured to leverage the unique talents of the executive team across the organization to capitalize on global brand and generic growth opportunities and to continue Actavis' focus on generating long-term, organic double-digit earnings growth.

Paul M. Bisaro, Executive Chairman

Paul M. Bisaro currently serves as Executive Chairman of Actavis and the Company's Board of Directors. He served as the Company's Chief Executive Officer from September 2007 to July 2014. Prior to joining Actavis (then Watson), he was President and Chief Operating Officer of Barr Pharmaceuticals, Inc. ("Barr") from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel and from 1997 to 1999 served in various additional capacities including Senior Vice President — Strategic Business Development. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. He also served as a Senior Consultant with Arthur Andersen & Co. Mr. Bisaro received his undergraduate degree in General Studies from the University of Michigan in 1983 and a Juris Doctor from Catholic University of America in Washington, D.C. in 1989.

Brenton L. Saunders, CEO and President

Brent Saunders was appointed Chief Executive Officer and President of Actavis effective July 1, 2014. Previously, he served as Chief Executive Officer and President of Forest Laboratories from 2013 to 2014 and served on the Company's Board of Directors since August 2011. Prior to joining Forest, he served as the Chief Executive Officer and board member of Bausch + Lomb Incorporated from March 2010 until August 2013. Mr. Saunders served as a senior executive with Schering-Plough from 2003 to 2010, most recently as President of Global Consumer Health Care. He also served as Head of Integration for both Schering-Plough's merger with Merck & Co. and for its \$16 billion acquisition of Organon BioSciences. Before joining Schering-Plough, Mr. Saunders was a Partner and Head of the Compliance Business

Advisory Group at PricewaterhouseCoopers LLP from 2000 to 2003. Prior to that, he was Chief Risk Officer at Coventry Health Care between 1998 and 1999 and a co-founder of the Health Care Compliance Association in 1995. Mr. Saunders began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. He received a B.A. from the University of Pittsburgh, an M.B.A. from Temple University School of Business, and a J.D. from Temple University School of Law.

Robert Stewart, COO

Bob Stewart was appointed Chief Operating Officer of Actavis effective July 1, 2014. Previously, Mr. Stewart served as President, Global Operations and Executive Vice President, Global Operations, since August 2010. Mr. Stewart is responsible for Global Operations, Quality, Supply Chain, Procurement, Engineering and Security and Information Technology, as well as Actavis' Global Brands, Generics and Biosimilars Research and Development (R&D). He joined Actavis (then Watson) in November 2009 as Senior Vice President, Global Operations. Prior to joining Watson, Mr. Stewart held various positions with Abbott Laboratories, Inc. from 2002 until 2009 where he most recently served as Vice President, Global Supply Chain. From 2005 until 2008, he served as Divisional Vice President, Quality Assurance and prior to this position served as Divisional Vice President for U.S./Puerto Rico and Latin America Plant Operations as well as Director of Operations for Abbott's Whippany plant. Prior to joining Abbott Laboratories, Inc., he worked for Knoll Pharmaceutical Company from 1995 to 2001 and Hoffman La-Roche Inc. Mr. Stewart received B.S. degrees in Business Management/Finance in 1994 from Fairleigh Dickinson University.

Bill Meury – Executive Vice President Commercial, North American Brands

Bill Meury was appointed Executive Vice President, Commercial, North American Brands effective July 1, 2014. Prior to joining Actavis, he served as Executive Vice President, Sales and Marketing, Forest Laboratories, Inc. He joined Forest in 1993 and held positions in Marketing, New Products, Business Development, and Sales. Most recently, as Executive Vice President, Sales and Marketing, Mr. Meury oversaw the activities of several departments including Product Management, Market Research, and Commercial Assessments, as well as Forest's Global Marketing and Early Commercialization groups. Mr. Meury directed 10 product launches during his tenure at Forest. Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. He has a B.S. in Economics from the University of Maryland.

David A. Buchen – Executive Vice President Commercial, North American Generic and International

David Buchen was appointed Executive Vice President, Commercial, North American Generics and International effective July 1, 2014. Previously, Mr. Buchen served as Chief Legal Officer – Global since 2012 and also served as Secretary to Actavis' Board of Directors. Mr. Buchen had served as Executive Vice President, General Counsel and Secretary since March 2011. He had previously served as Senior Vice President, General Counsel and Secretary since November 2002. From November 2000 to November 2002, Mr. Buchen served as Vice President and Associate General Counsel. From February 2000 to November 2000, he served as Vice President and Senior Corporate Counsel. From November 1998 to February 2000, he served as Senior Corporate Counsel and as Corporate Counsel. He also served as Assistant Secretary from February 1999 to November 2002. Prior to joining Watson, Mr. Buchen was Corporate Counsel at Bausch & Lomb Surgical (formerly Chiron Vision Corporation) from November 1995 until November 1998 and was an attorney with the law firm of Fulbright & Jaworski, LLP. Mr. Buchen received a B.A. in Philosophy from the University of California, Berkeley in 1985, and a Juris Doctor with honors from George Washington University Law School in 1989.

R. Todd Joyce, Chief Financial Officer

Todd Joyce was appointed Actavis' Chief Financial Officer on April 27, 2012. Mr. Joyce had served as Executive Vice President, Chief Financial Officer since March 2011. He had previously served as Senior Vice President, Chief Financial Officer since October 2009. He joined Actavis (then Watson) in 1997 as Corporate Controller, and was named Vice President, Corporate Controller and Treasurer in 2001. During the periods October 2006 to November 2007 and from July 2009 until his appointment as Chief Financial Officer, Mr. Joyce served as interim Principal Financial Officer. Prior to joining Watson, Mr. Joyce served as Vice President of Tax from 1992 to 1996 and as Vice President of Tax and Finance from 1996 until 1997 at ICN Pharmaceuticals. Prior to ICN Pharmaceuticals, Mr. Joyce served as a Certified Public Accountant with Coopers & Lybrand and Price Waterhouse. Mr. Joyce received a B.S. in Business Administration from the University of North Carolina at Chapel Hill in 1983 and a M.S. in Taxation from Golden Gate University in 1992.

Bob Bailey – Chief Legal Officer

Bob Bailey was appointed Chief Legal Officer and Corporate Secretary effective July 1, 2014. Previously, Mr. Bailey served as Senior Vice President, Chief Legal Officer, General Counsel and Corporate Secretary of Forest Laboratories, Inc. He previously served from 2007 to 2013 as Executive Vice President, Law, Policy and Communications at Bausch + Lomb. Before joining Bausch + Lomb in 1994, Mr. Bailey was an attorney at Nixon Peabody (formerly Nixon

Hargrave Devans & Doyle). Mr. Bailey received his law degree from the University of Minnesota and his undergraduate degree from St. Olaf College in Northfield, MN.

Karen Ling – Chief Human Resources Officer

Karen Ling was appointed Chief Human Resources Officer effective July 1, 2014. Prior to joining Actavis, Ms. Ling served as Senior Vice President and Chief Human Resources Officer for Forest Laboratories, Inc. Ms. Ling joined Forest in January 2014 from Merck & Co., Inc., where she served as Senior Vice President, Human Resources, for the company's Global Human Health and Consumer Care businesses worldwide. Prior to that role at Merck, she was Vice President, Compensation and Benefits. Before Merck, Ms. Ling was Group Vice President, Global Compensation & Benefits at Schering-Plough. She also spent 14 years at Wyeth in various positions of responsibility in human resources as well as in Wyeth Pharmaceutical's Labor and Employment Department. Prior to joining Wyeth, Ms. Ling practiced corporate law with Goldstein and Manello, P.C. in Boston. Ms. Ling holds a B.A. from Yale University and a J.D. from Boston University School of Law.

Charlie Mayr – Chief Communications Officer

Charlie Mayr was appointed Actavis Chief Communications Officer on April 27, 2012. Mr. Mayr joined Actavis (then Watson) as Senior Vice President, Corporate Affairs in September 2009. Prior to joining Watson, Mr. Mayr operated an advertising and public relations consulting company from 1998 to 2009, serving such clients as Watson, the Generic Pharmaceutical Association (GPhA), Barr Pharmaceuticals and a variety of professional associations and consumer products and service companies. Prior to starting his consultancy business, he served as Director of Corporate Communications for Barr Pharmaceuticals, Inc. from 1994 to 1998. Prior to joining Barr, he served as Director of Global Communications from 1990 to 1994 for Sterling Drug Inc., the global brand and consumer health products pharmaceutical subsidiary of Kodak. Mr. Mayr began his career as a broadcast and print journalist and has a B.A. in journalism from New York University.

About Actavis

Actavis plc (NYSE:ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical

industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

For more information, visit Actavis' website at www.actavis.com.